CommercialCoverageMedium impact
06.02.30f, Pharmacogenetic Testing to Determine Drug Sensitivity (Independence Administrators)
Independence Blue Cross·Pharmacy·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators reissued policy 06.02.30f on pharmacogenetic testing for drug sensitivity, effective October 1, 2025. Without access to the full policy text content, specific coverage criteria, billing code requirements, prior authorization mandates, or changes from the previous version cannot be determined. The billing team must obtain and review the complete policy document to identify actionable changes.
Action Required
By October 1, 2025: Billing team must obtain the full text of policy 06.02.30f from the Independence Administrators website (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-30f) and review complete coverage criteria, covered CPT/HCPCS codes for pharmacogenetic testing, prior authorization requirements, medical necessity documentation standards, and any changes from the previous policy version. Update billing system rules, prior authorization workflows, and provider education materials accordingly. Identify affected test codes and update billing software to enforce new requirements. Failure to implement policy requirements may result in claim denials for non-compliant submissions.